Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 4/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.78 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.78 |
| ▸ | THPO | P40225 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.78 |
| ▸ | ACHE | P22303 | 1/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.78 |
| ▸ | DRD3 | P35462 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL766080 | 0.94 | CYP3A4 (0.70) | HIF1ACYP3A4ALDH1A1SMN1; SMN2LMNA | |
| Sarcolysin SCHEMBL28338888 | 0.88 | HIF1A (0.94) | HIF1ACYP3A4ALDH1A1SMN1; SMN2LMNA | |
| Melphalan SCHEMBL4697634 | 0.88 | HIF1A (0.94) | HIF1ACYP3A4ALDH1A1SMN1; SMN2LMNA | |
| Melphalan SCHEMBL563239 | 0.88 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2LMNA | |
| (R)-Melphalan SCHEMBL5873 | 0.88 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2LMNA | |
| Melphalan SCHEMBL5872 | 0.88 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2LMNA | |
| Melphalan SCHEMBL5325132 | 0.88 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2LMNA | |
| Sarcolysin SCHEMBL414671 | 0.88 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2LMNA | |
| Melphalan SCHEMBL41335 | 0.86 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2LMNA | |
| Melphalan SCHEMBL2723742 | 0.86 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| WO-2021024041-A1 | CONTROLLED RELEASE DRUG DIMERS | RIPPLE THERAPEUTICS CORPORATION (CA) | 2021-02-11 | — | — | WO | disclosed |
| US-10004735-B2 | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | SIGNAL PHARMACEUTICALS, LLC (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180148473-A1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | ONCOPEPTIDES AB (SE) | 2018-05-31 | — | — | US | disclosed |
| US-9963422-B2 | Process for the synthesis of melphalan and the hydrochloride salt | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2018-05-08 | — | — | US | disclosed |
| US-20170312278-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY COMPRISING ADMINISTERING SUBSTITUTED PYRAZINO[2,3-b]PYRAZINES | SIGNAL PHARM LLC (US) | 2017-11-02 | — | — | US | disclosed |
| WO-2016203337-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | MOHAN M ALAPATI (IN) | 2016-12-22 | — | — | WO | disclosed |
| WO-2014141057-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | KANDULA MAHESH (IN) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | HIF1A 2325/4885CYP3A4 4674/4885ALDH1A1 4380/4885 |
| US-20180148473-A1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | CBR3, GRHPR, CTH | HIF1A 1283/4885CYP3A4 205/4885ALDH1A1 1092/4885 |
| US-10004735-B2 | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | MTOR, ULK2, TTK | HIF1A 1738/4885CYP3A4 3016/4885ALDH1A1 4336/4885 |
| US-20170312278-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY COMPRISING ADMINISTERING SUBSTITUTED PYRAZINO[2,3-b]PYRAZINES | MTOR, ULK2, TTK | HIF1A 1738/4885CYP3A4 3016/4885ALDH1A1 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.